Narendorf, Sarah C.2021-08-262021-08-26May 20212021-05May 2021https://hdl.handle.net/10657/8109Introduction: The survival of women with breast cancer depends on treatment-completion. We explored factors that promote treatment-completion and reduce aromatase inhibitor (AI) medication switching. We evaluated the effect of any Integrative Medicine (IM) clinic use on those outcomes. Methods: Means, frequencies, modified Poisson regression analysis, and propensity score analysis were used to examine three samples of women with hormone receptor-positive breast cancer treated with taxane chemotherapy or hormone therapy between 1/1/2009-12/31/2019 at MD Anderson Cancer Center. Treatment-completion was defined as a relative dose-intensity(RDI) of ≥85% for chemotherapy, or ≥54 months with a hormone therapy prescription; AI switching was also assessed. Sample: There were 508, 3764, and 2253 women in the chemotherapy, hormone therapy, and AI switching samples, respectively. Results: We found that 53.1% of patients completed chemotherapy, 64.3% of patients completed hormone therapy, and 68.8% of patients took just one AI medication. Less pain (RR, 0.97; 95%CI, 0.95 to 0.98; p<0.001) and SF-12 PCS (RR 1.03; 95%CI: 1.02 to 1.05; p<0.001) were associated with increase probability of hormone therapy treatment-completion in bivariate analysis. Differences between IM clinic users and non-users were not statistically significant among the samples. Discussion: Many women did not complete treatment. Two quality-of-life measures were related to hormone therapy treatment-completion. Treatment-completion of IM clinic users were not different from non-users. Some predictors of treatment-completion are changeable and warrant a central focus during treatment. Future research should include more IM treatments (e.g., 8 acupuncture treatments) for the inclusion criteria.application/pdfengThe author of this work is the copyright owner. UH Libraries and the Texas Digital Library have their permission to store and provide access to this work. Further transmission, reproduction, or presentation of this work is prohibited except with permission of the author(s).Breast CancerTreatment-CompletionRelative Dose IntensityIntegrative MedicinePropensity Score2021-08-26Thesisborn digital